|Title||Regulatory workshop on clinical trials designs in neuromyelitis optica (NMO) and spectrum disorders|
|Date||10/10/2014 - 10/10/2014|
|Location||European Medicines Agency, London, UK|
|Summary||This workshop brings together patient representatives, healthcare professionals, regulators, Pharma and ethicists to discuss trial designs in NMO, a rare neurological disorder. For evidence of efficacy, in NMO, the choice of comparator is problematic. The severity/lack of reversibility of NMO relapses, indicate that placebo comparators are difficult but evidence for current treatments appears lacking. Different regulatory agencies have different views on comparators in NMO attack prevention. For a rare debilitating disease with unmet medical need, a wider debate is being held to facilitate drug development for the benefit of NMO patients. See 'Documents’ tab for agenda and 'Multimedia' tab for video of the workshop.|
|Name||Language||First published||Last updated|
|Agenda - Regulatory workshop on clinical trials designs in neuromyelitis optica (NMO) and spectrum disorders||(English only)||07/07/2014||07/10/2014|
|Registration form - Regulatory workshop on clinical trials designs in neuromyelitis optica (NMO) and spectrum disorders||(English only)||07/07/2014|
To view the broadcast, please ensure that Adobe Flash Player is installed.
Note that you should see the live broadcast or the message ‘We are currently not broadcasting’ below, on this page. If the area below is black or in case of difficulties viewing the broadcast, please try connecting directly to our Ustream channel: European Medicines Agency or try viewing from an unrestricted connection, for example over wifi or 3G. For technical information about the required network security settings, please see this Ustream help page.
For further assistance, please consult the Ustream Help Center.